As a promising first step, risdiplam has been found to increase SMN-P blood levels in animal models and humans with SMA [15], indicating that this peripheral increase might reflect levels in other peripheral organs such as muscle, or the CNS [54] (see Table 1). This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.